1,405 results on '"Sparano, Joseph A"'
Search Results
52. Human Immunodeficiency Virus (HIV) Infection and Cancer
53. Contributors
54. Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population
55. Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)
56. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer
57. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer
58. Serum levels of several molecules that are associated with B cell activation and inflammation are elevated in AIDS-associated non-Hodgkin’s lymphoma (AIDS-NHL) and predict response to treatment
59. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
60. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer
61. Supplementary Data Table 2 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
62. Data from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
63. Supplementary Data Table 1 from Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
64. Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer
65. The Tumor Microenvironment as a Metastasis Biomarker in Breast Cancer
66. If we build it they will come: targeting the immune response to breast cancer
67. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
68. Supplemental table 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
69. Table S1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
70. Supplementary Table 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
71. Supplementary Figure 2 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
72. Supplementary Figure 1 from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
73. Supplementary Table S1 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
74. Supplementary Figure 1 from Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
75. Supplementary Figure Legends from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
76. Supplementary Figure 1 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
77. Supplementary Figure 6 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
78. Supplementary Table 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
79. Supplementary Figure 2 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
80. Supplementary Tables 1 - 2 from Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
81. Supplemental Table 1. from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
82. Supplementary Table 2 from Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
83. Supplementary Data from Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer
84. Supplementary Figure 5 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
85. Supplementary Figure 3 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
86. Supplemental Table 2 from Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
87. Supplementary Data from Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study
88. Data from Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
89. Supplementary Figure 1 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
90. Supplementary Figure 7 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
91. Supplementary Figure 4 from Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma
92. Supplementary Table 3 from Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer
93. Supplementary Figure S2 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
94. Abstract P3-05-26: Association of muscle mass and density with outcomes in patients with ER positive metastatic breast cancer: correlative analysis of ECOG-ACRIN 2112
95. Abstract PD1-09: Associations between the 21-gene Oncotype DX Recurrence Score (RS), Ki67, and Race in Early Breast Cancer (EBC) Using the National Cancer Database (NCDB)
96. Abstract OT1-11-01: Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping
97. Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates
98. Abstract GS1-02: Racial disparity in tumor microenvironment and outcomes in residual breast cancer treated with neoadjuvant chemotherapy
99. The ESC Cardio-Oncology Guidelines
100. Cooperative Groups and Global Clinical Trials in the Future
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.